Key Analysts at Robert W. Baird Maintained their ‘”Buy”’ rating for PRA Health Sciences (NASDAQ:PRAH) Shares Today. Their Target Given is $94.0

March 14, 2018 - By Hazel Jackson

 Key Analysts at Robert W. Baird Maintained their ‘

PRA Health Sciences (NASDAQ:PRAH) Rating Reaffirmed

PRA Health Sciences (NASDAQ:PRAH) just had their share rating of a ‘”Buy”‘ issued by research analysts at Robert W. Baird, who now has a $94.0 target price on the $5.79B market cap company or a 3.64 % upside potential. This key information was disclosed in an analyst note on Thursday, 30 November.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings Coverage

Among 15 analysts covering PRA Health Sciences (NASDAQ:PRAH), 10 have Buy rating, 0 Sell and 5 Hold. Therefore 67% are positive. PRA Health Sciences has $110.0 highest and $43 lowest target. $92.08’s average target is 1.52% above currents $90.7 stock price. PRA Health Sciences had 42 analyst reports since July 22, 2015 according to SRatingsIntel. The company was maintained on Monday, October 9 by Robert W. Baird. The company was maintained on Monday, October 16 by KeyBanc Capital Markets. The firm has “Buy” rating by Mizuho given on Friday, December 1. The firm has “Buy” rating by SunTrust given on Monday, January 22. The firm has “Buy” rating by Jefferies given on Monday, September 11. On Tuesday, August 8 the stock rating was maintained by Credit Suisse with “Outperform”. The stock has “Neutral” rating by SunTrust on Thursday, November 19. The company was maintained on Thursday, September 22 by Citigroup. The firm earned “Buy” rating on Tuesday, January 30 by KeyBanc Capital Markets. Jefferies maintained the shares of PRAH in report on Friday, October 27 with “Buy” rating.

The stock decreased 1.59% or $1.47 during the last trading session, reaching $90.7. About 389,012 shares traded. PRA Health Sciences, Inc. (NASDAQ:PRAH) has risen 52.22% since March 14, 2017 and is uptrending. It has outperformed by 35.52% the S&P500.

Analysts await PRA Health Sciences, Inc. (NASDAQ:PRAH) to report earnings on April, 24. They expect $0.77 EPS, up 28.33 % or $0.17 from last year’s $0.6 per share. PRAH’s profit will be $49.12 million for 29.45 P/E if the $0.77 EPS becomes a reality. After $1.04 actual EPS reported by PRA Health Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.96 % negative EPS growth.

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company has market cap of $5.79 billion. The firm offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It has a 68.71 P/E ratio. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

More recent PRA Health Sciences, Inc. (NASDAQ:PRAH) news were published by: which released: “Pre-Market Technical Scan on Medical Research Equities — HTG Molecular …” on March 12, 2018. Also published the news titled: “PRA Health Sciences Receives CRO Leadership Award” on March 14, 2018.‘s news article titled: “PRA Health Sciences Named Best CRO in Asia” with publication date: March 06, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: